LMR Partners’s Rocket Pharmaceuticals Warrant RCKTW Stock Holding History

LMR Partners’s Portfolio RCKTW Stock Details RCKTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.56K	Hold	75,731	–	–	﹤0.01%	1406
2025 Q4	$1.84K	Hold	75,731	–	–	﹤0.01%	1476
2025 Q3	$2.97K	Hold	75,731	–	–	﹤0.01%	1407
2025 Q2	$2.98K	Hold	75,731	–	–	﹤0.01%	1319
2025 Q1	$3.56K	Hold	75,731	–	–	﹤0.01%	1295
2024 Q4	$2.6K	Buy	+75,731	New	+$3.7K	﹤0.01%	1148
2024 Q3	–	Sell	-60,771	Closed	-$4.68K	–	1475
2024 Q2	$3.69K	Hold	60,771	–	–	﹤0.01%	1051
2024 Q1	$18.2K	Hold	60,771	–	–	﹤0.01%	1035
2023 Q4	$29.8K	Hold	60,771	–	–	﹤0.01%	820
2023 Q3	$10.3K	Hold	60,771	–	–	﹤0.01%	818
2023 Q2	$11.5K	Buy	+60,771	New	+$11.1K	﹤0.01%	762

Other funds holding RCKTW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LMR Partners's RCKTW Position: Q1 2026 in Review

LMR Partners held its Rocket Pharmaceuticals Warrant (RCKTW) position steady in Q1 2026 at 75,731 shares worth $1.56K. The position accounts for ﹤0.01% of the portfolio, ranked #1406.

LMR Partners first reported a position in RCKTW in Q2 2023 and has held it in 11 quarters since. The position peaked at $29.8K in Q4 2023. 10 funds tracked by Wall St. Rank hold RCKTW as of Q1 2026.

LMR Partners held 75,731 shares of Rocket Pharmaceuticals Warrant worth $1.56K as of Q1 2026.
LMR Partners left its Rocket Pharmaceuticals Warrant share count unchanged in Q1 2026.
Rocket Pharmaceuticals Warrant made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1406 holding.
LMR Partners first reported a position in Rocket Pharmaceuticals Warrant in Q2 2023 and has held it in 11 quarters since.
LMR Partners's Rocket Pharmaceuticals Warrant position peaked at $29.8K in Q4 2023.
10 funds tracked by Wall St. Rank held Rocket Pharmaceuticals Warrant as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.